SunBio
선바이오 · 067370
Health Care Pharmaceuticals · KOSDAQ
Market cap US$58.1M (₩80.2B)
Overview
SunBio develops and supplies PEG (polyethylene glycol) derivatives, chemical building blocks used to make biopharmaceutical drugs, and has its own drug products, including a treatment for a condition called neutropenia (a dangerous drop in white blood cells caused by chemotherapy) and a dry-mouth therapy.
Its neutropenia drug is supplied to Intas Pharma, which manufactures the finished product for markets including the EU, Canada, Australia, and India, with SunBio earning royalties on those sales. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company's core revenue engine is its PEG-derivative supply and royalty business, while it also runs early-stage research into artificial blood and solid-state battery electrolytes.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$8.9M
- FY2024US$6.3M
- FY2025US$9.9M
Operating profit
- FY2023US$3.8M
- FY2024−US$386.4K
- FY2025US$3.6M
Net income
- FY2023US$3.3M
- FY2024−US$75.6K
- FY2025US$2M
Key ratios (FY2025)
Why it matters
SunBio's PEG-derivative and drug businesses are built on its proprietary pegylation technology platform, which it is also applying to new areas such as lipid nanoparticle stabilization and battery electrolytes.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?